Recent News

• 11.24.2025 - Lantheus to Present Florbetaben F 18 Data at CTAD 2025
• 11.24.2025 - Lantheus to Present Florbetaben F 18 Data at CTAD 2025
• 11.06.2025 - Q3 2025 Lantheus Earnings Conference Call
• 11.06.2025 - Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.06.2025 - Lantheus Announces Leadership Transition Plan
• 11.06.2025 - Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.06.2025 - Lantheus Announces Leadership Transition Plan
• 10.30.2025 - Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
• 10.30.2025 - Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
• 10.28.2025 - Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease

Recent Filings

• 11.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 8-K Current report
• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors